Sinovision Secures RMB 200 Million Series D Funding to Expand from Imaging to Multidisciplinary Diagnosis and Treatment

On December 31, Sinovision Technology (Beijing) Co., Ltd. (hereinafter referred to as “Sinovision”) announced that it had secured RMB 200 million in Series D financing, jointly led by Yangzhou Longtou Houde Emerging Industry Investment Partnership (Limited Partnership) and Shenzhen Capital Group.

It is reported that the funds raised in this round will be used to increase R&D investment in CT imaging and tackle key core technologies, further accelerating the deployment of 5G + robot-navigated products across medical institutions at all levels; promoting the multidisciplinary development of medical imaging from diagnosis to treatment; and accelerating the application of AI-based imaging in the construction of smart healthcare and internet healthcare.

Since its establishment in 2012, Sinovision, with over eight years of development, has gradually evolved from an obscure medical device manufacturer into a leading domestic CT giant. Today, the intelligent CT solutions from Sinovision can be seen in numerous hospitals across China.

Over the past eight years, Sinovision has progressively refined its product portfolio. As a provider of high-end X-ray medical imaging equipment, Sinovision offers products and services including X-ray computed tomography (CT) scanners, the sROBOT robotic CT navigation system, and the sAI intelligent imaging solution. Its independently developed large-bore CT series and core components have filled the gap for domestic brands in this field. Leveraging the clinical advantage of multi-functional capability in a single unit, Sinovision makes high-end medical imaging technology accessible to a broader population.

Sinovision has chosen a CT niche that few domestic players have entered. In the early 1990s, annual sales of CT imaging equipment in China stood at only around 200 units; this year, that figure has exceeded 4,000 units, representing more than a 20-fold increase.

Behind the enormous market potential lies China’s relatively low penetration rate of large-scale medical devices and its low pharmaceutical-to-medical-device ratio. Statistical data from 2018 show that the total installed base of CT scanners in China was approximately 30,000 units, equivalent to 16.8 units per million people. In contrast, developed countries with more robust medical equipment infrastructure have significantly higher figures: Japan has 92.6 CT scanners per million people, and the United States has 32.2 per million. Regarding the pharmaceutical-to-medical-device ratio, China’s current ratio stands at 1:0.19, far below the global average of 1:0.7, while in developed countries, this ratio reaches 1:0.98.

The emergence of the COVID-19 pandemic has further intensified the demand for CT scanners among primary healthcare institutions. Unlike tertiary hospitals, this segment prioritizes diagnostic functions over therapeutic ones, driving their preference for mid- to low-end CT systems. This aligns precisely with the vision of Sinovision Technology (Beijing) Co., Ltd., which aims to provide cost-effective CT products for primary care settings.

During the pandemic, Sinovision further expanded its CT product line by developing a vehicle-mounted whole-body CT system equipped with an intelligent processing workstation, the SinoCloud platform, and 5G technology. This intelligent mobile CT vehicle utilizes a high-power traction head and a heavy-duty chassis to achieve high mobility and stability. It is fitted with an integrated self-loading and unloading mechanism to ensure balanced positioning during operation, addressing the challenges of setting up fever clinics in certain areas and providing effective safety protection for healthcare workers.

To further expand CT capabilities, Sinovision Technology has developed a robotic surgical navigation system integrated with 5G medical technology. This CT image-guided percutaneous interventional procedure assists interventional radiologists in performing biopsies, fine-needle aspiration cytology, radiofrequency ablation, drainage, and pain management. Leveraging 5G technology, remote minimally invasive oncological surgeries have become feasible, thereby promoting the widespread adoption of interventional therapies.

Currently, surgery, chemotherapy, and radiotherapy remain the primary treatment modalities for malignant tumors. While these three approaches play a significant role, their drawbacks are evident; they often cause substantial collateral damage to healthy tissues, inevitably harming the patient’s normal physiological structures and significantly compromising quality of life. Interventional oncology offers advantages such as minimal invasiveness, lower cost, safety, and favorable efficacy. However, interventional tumor procedures can only be performed by experienced physicians at tertiary care centers, as primary healthcare institutions generally lack the capability to conduct such surgeries.

With the assistance of 5G technology and robotic navigation systems, physicians at primary-care hospitals can perform minimally invasive surgeries. This enables cancer patients to undergo surgical procedures at regional hospitals, substantially reducing both the time and financial burdens associated with seeking medical care, thereby effectively addressing the longstanding challenges of difficult and costly access to healthcare and supporting the national tiered diagnosis and treatment policy’s goal of “managing serious illnesses within the county.” The integration of 5G technology with robotic navigation–guided surgical systems will benefit millions of cancer patients.

Strengthening primary care is key to implementing the tiered diagnosis and treatment policy, while private hospitals are a vital force in healthcare services. How can primary care be effectively strengthened, and how can the quality of diagnostic and therapeutic services provided by private hospitals be ensured? Sinovision’s sAI intelligent imaging solutions provide robust support for cost reduction, efficiency improvement, and service enhancement in lower-tier hospitals, including private and primary care institutions.

The SinoCloud system offers remote image interpretation and reporting capabilities, assisting lower-tier hospitals in diagnosing complex cases and rapidly enhancing their diagnostic and treatment capacities. It also facilitates multi-site practice by specialists and the implementation of tiered diagnosis and treatment, while enabling the establishment of the SinoCloud regional consultation network and the SinoCloud Medical Consortium framework.

Cloud-based experts draft imaging reports and provide high-quality diagnostic reports based on patient imaging data and basic medical history uploaded by subordinate hospitals to SinoCloud.

Meanwhile, for complex cases, lower-tier hospitals can initiate imaging consultations and even multidisciplinary team (MDT) consultations to resolve diagnostic challenges, shorten waiting times for diagnosis and treatment, formulate reasonable treatment plans, minimize misdiagnosis and mistreatment, and alleviate the burden on patients’ families caused by repeated referrals and redundant examinations. Furthermore, lower-tier hospitals can leverage Sinovision Cloud to conduct training for medical technologists, implement quality control for imaging examinations, advance the development of radiology departments, and promote clinical single-disease management programs.

SainoCloud breaks through the limitations of space and time, delivering expert resources from central hospitals in major cities to lower-tier hospitals and patients via the cloud. On one hand, it effectively compensates for the shortage of radiology personnel and experience in lower-tier hospitals, enhancing their imaging diagnostic capabilities. On the other hand, it saves patients time and costs associated with medical consultations.

Sinovision’s independently developed sAI intelligent imaging solution provides customers with comprehensive advanced processing and visualization capabilities, covering clinical departments such as cardiology, neurology, thoracic and abdominal medicine, and orthopedics. By leveraging advanced visualization tools and customizable workflows, the solution enhances diagnostic efficiency and assists physicians in making high-precision medical diagnoses and decisions.

With the advent of an aging society, global demand for medical imaging equipment continues to grow. CT scanners can serve nearly all clinical departments and are applicable to the diagnosis and treatment of diseases in every part of the body, leading to a sustained rise in market demand. During the fight against the global COVID-19 pandemic, the importance of CT was rapidly highlighted, with CT imaging findings designated as a diagnostic criterion for clinically diagnosed cases of COVID-19.

Sinovision is dedicated to the research and development of CT technology, closely integrating core CT capabilities with clinical needs. This approach has opened new frontiers in precise tumor localization and minimally invasive interventional oncology procedures, significantly advancing the implementation of precision medicine and efficient treatment. Furthermore, it holds promise for promoting the widespread adoption of minimally invasive interventional tumor surgeries across China, thereby benefiting millions of cancer patients.

To date, Sinovision’s CT systems have been installed at numerous large, comprehensive Grade 3A hospitals, including Peking Union Medical College Hospital and Beijing Tiantan Hospital affiliated with Capital Medical University, earning high recognition from these institutions. Its end users span more than 400 healthcare institutions across over 30 countries and regions worldwide.

Hao Chuanfu, Managing Director of Yangzhou Longtou Houde Emerging Industry Investment Partnership (Limited Partnership), stated, “Over the past few years, we have been closely monitoring the development of Sinovision. Its strong R&D capabilities, flexible market strategies, high product quality, and positive user reputation are the primary reasons for our interest. Furthermore, we believe that multi-energy CT can better align with clinical needs, extending the diagnostic functions of CT into clinical practice and treatment, with very broad future prospects.” Lin Yunyu, Investment Director at Shenzhen Capital Group, commented, “As a medical imaging equipment company specializing in CT devices, the vitality and capabilities demonstrated by Sinovision are core qualities we highly value. The domestic substitution of CT equipment, accelerated by the outbreak of the pandemic, has entered a phase of rapid, explosive growth, driven by strong market forces. We are very optimistic about the company’s development.”